View Older Stories View More Recent Stories
-
Moving Minds Selected as One of the Top SEO Companies in U.S. by RankWatch
-
Adela Appoints Precision Medicine Veteran Lisa Alderson as CEO
-
Titans Gather, Future Embarks: The GenScript Biotech Global Forum coinciding with the 2024 J.P. Morgan Healthcare Conference in San Francisco to Convene 20+ KOLs, Exploring Disruptive Transformations
-
Bicara Therapeutics Announces Oversubscribed $165 Million Series C Financing
-
Deerfield Foundation Awards More Than $1.4 Million to Improve Health, Accelerate Innovation and Promote Equity
-
Publication Relating to a Transparency Notification
-
CRISPR Continuous to Innovate! Exploring the Future of Cell & Gene Therapy, Industry Leaders Converge at the 2024 GenScript Biotech Global Forum
-
Adela Presents Data Demonstrating Strong Prognostic Prediction Capabilities in Lung Cancer at the 2023 Multidisciplinary Thoracic Cancers Symposium
-
Form 4 CareMax, Inc. For: Nov 17 Filed by: DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
-
Oscar Health (OSCR) Reports Mark Bertolini’s Foundation and Deerfield Management have Agreed with a Selling Shareholder to Purchase Shares of Oscar Health
-
Oscar Health, Inc. Announces that Mark Bertolini’s Foundation and Deerfield Management have Entered into an Agreement with a Selling Shareholder to Purchase Shares of Oscar Health
-
Form 13F-HR DEERFIELD MANAGEMENT For: Sep 30
-
Element Science Announces Presentation of Successful Results of the Jewel® IDE Study in a Featured Science Presentation at the American Heart Association’s 2023 Annual Scientific Sessions
-
Endologix to Present in Two Upcoming Healthcare Conferences
-
Valneva Reports Nine-Month 2023 Financial Results and Provides Corporate Updates
-
Sfunga Therapeutics and Deerfield Management Announce Publication on Novel Antifungal SF001 in Nature
-
Endologix Announces Results of Pooled Analysis of DETOUR1 and DETOUR2 Studies at 2023 VIVA Late-Breaking Clinical Trial Session
-
CYSTETIC MEDICINES DOSES FIRST PERSON WITH CYSTIC FIBROSIS IN PHASE 1 TRIAL OF INVESTIGATIONAL THERAPY CM001, DESIGNED TO FORM ION CHANNELS TO HELP RESTORE AIRWAY FUNCTION
-
Endologix's DETOUR™ System Earns Spot in Local and National Award Forums; Nominated for Prix Galien USA's Best Medical Technology
-
Adela Presents Data Demonstrating Strong Prognostic Prediction Capabilities in Head and Neck Cancer and Renal Cell Carcinoma at the ESMO 2023 Congress
-
MMI Expands Global Footprint with Entry into Asia Pacific Market
-
Late-Breaking Data Confirms Safety of Axon Therapies' Innovative Heart Failure Procedure and Identifies Patients Most Likely to Benefit from SAVM Therapy
-
Aviko Radiopharmaceuticals and Neutron Therapeutics Form Exclusive, Strategic Partnership with Leo Cancer Care to Expand Development of Boron Neutron Capture Therapy for Treating Cancer
-
Adela Announces $48 Million in Financing and Leadership Addition to Advance Tissue-Agnostic Minimal Residual Disease (MRD) Monitoring Product Portfolio Based on Genome-Wide Methylome Approach
-
MMI’s Symani® Robotic Surgical System Surpasses 500 Clinical Procedures
-
Cure® Makes Commitment with Clinton Global Initiative to Advance Healthcare Through Partnerships Acting on Pressing Global Health Challenges and Opportunities
-
Actio Biosciences Announces $55 Million Series A Financing to Advance Precision Medicine Approach for Rare and Common Diseases
-
Cure® to Host Science Summit of 78th United Nations General Assembly
-
Endologix announces the U. S. Centers for Medicare & Medicaid Services granted a New Technology Add-on Payment for the DETOUR System
-
Endologix Announces that Lucas Buchanan Joins Board of Directors
-
Valneva Announces Extension of Existing Loan Agreement
-
Form 13F-HR DEERFIELD MANAGEMENT For: Jun 30
-
Form SC 13D/A DA32 Life Science Tech Filed by: DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
-
End in sight for U.S. insider trading case over healthcare leaks
-
Octave Bioscience Closes $30M Extension to Series B Funding
-
Endologix Announces First Patients Treated with the DETOUR™ System, Advancing Treatment for Complex Peripheral Artery Disease
-
Presidio Medical™ Announces $72M Equity Fundraising Led by Deerfield
-
cystetic Medicines Initiates Phase 1 Clinical Trial of a Molecular Prosthetic for Cystic Fibrosis
-
Form 4 Acutus Medical, Inc. For: Jun 16 Filed by: DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
-
Form 4 Nuvalent, Inc. For: Jun 15 Filed by: DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
-
Endologix Announces 24-Month Results of DETOUR-2 Study at 2023 Vascular Annual Meeting
-
LSI USA Emerging Medtech Summit Returns to Dana Point March 18, 2024
-
Adaptive Phage Therapeutics Closes on $12 Million Investment in $30 Million Series B1 to Fight Antibiotic Resistant Infections
-
Form 4 CareMax, Inc. For: Jun 08 Filed by: DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
-
Deerfield Management and the Deerfield Foundation Announce the Creation of the American Society of Hematology (ASH) Peter Steelman Scholar Award and the First Annual AML Summit to Advance Research for
-
Endologix Receives FDA Approval of the DETOUR™ System to Treat Long Complex Superficial Femoropopliteal Lesions in Patients with PAD
-
Aviko Radiopharmaceuticals and Neutron Therapeutics Form Strategic Partnership to Advance Boron Neutron Capture Therapy
-
Bitterroot Bio Launches Out of Stealth with $145 Million Series A Financing to Develop Transformative Medicines in Cardio-immunology
-
NYU Langone Health and Deerfield Management Launch Amethyst Innovations with Up To $130 Million to Accelerate Commercialization of Biomedical Discoveries
-
Adaptive Phage Therapeutics Enters Collaboration and License Agreement with Hebrew University of Jerusalem and Hadassah Medical Center
